| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3282454 | Clinical Gastroenterology and Hepatology | 2013 | 12 Pages |
Abstract
Among patients given dabigatran for atrial fibrillation, NB-UGI AEs are generally mild or moderate; 4% stopped taking the drug over a median of 21.7 months. The greatest increase was in GERD-type NB-UGI AEs. These observations should guide management and prevention strategies. ClinicalTrials.gov number, NCT00262600.
Keywords
NSAIDPPIFDAGERDUGIMedDRAH2RAgastroesophageal reflux diseasePost hoc analysisRelative risknonsteroidal anti-inflammatory drugGastrointestinalMedical Dictionary for Regulatory ActivitiesFood and Drug AdministrationToxicityadverse eventSide effectconfidence intervalProton pump inhibitorClinical trialUpper gastrointestinal
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Peter Bytzer, Stuart J. Connolly, Sean Yang, Michael Ezekowitz, Stephan Formella, Paul A. Reilly, James Aisenberg,